Please use this identifier to cite or link to this item:
http://repositorio.ufla.br/jspui/handle/1/28473
Title: | Docking studies and effects of syn-anti isomery of oximes derived from pyridine imidazol bicycled systems as potential human acetylcholinesterase reactivators |
Keywords: | Acetylcholinesterase Docking studies Oximes Neurotoxic agents Theoretical calculation Acetilcolinesterase Estudos de docagem Oximas Agentes neurotóxicos Cálculo teórico |
Issue Date: | 2011 |
Publisher: | Elsevier |
Citation: | GUIMARÃES, A. P. et al. Docking studies and effects of syn-anti isomery of oximes derived from pyridine imidazol bicycled systems as potential human acetylcholinesterase reactivators. Journal of Applied Biomedicine, [S. l.], v. 9, n. 3, p. 163-171, 2011. |
Abstract: | In order to contribute to a better understanding of the mechanism of action of oximes, we evaluated the affinities of 10 new oximes, derived from pyridine-imidazol bicycled systems, for human acetylcholinesterase (HssAChE) complexed with tabun, by estimating their docking energy values and comparing of the values obtained to known oximes using the software Molegro Virtual Docker (MVD)® We evaluated the influence of the position of the oxime group as substituent in the structures and, also, the influence of the oxime group syn-anti isomery on the docking score values for all the molecules studied. Results suggest that: the affinities of the 10 new oximes for the tabun inhibited HssAChE active site are better than pralidoxime's and similar to trimedoxime's; the meta-pralidoxime could have more affinity for the HssAChE active site and the oximes’ anti isomers could present slightly better affinities for the HssAChE active site than the syn isomers. |
URI: | https://www.sciencedirect.com/science/article/pii/S1214021X14600363#! http://repositorio.ufla.br/jspui/handle/1/28473 |
Appears in Collections: | DQI - Artigos publicados em periódicos |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.